118 results about "Nephrosis" patented technology

This invention discloses an N-alkoxyacetamide compound, its pharmaceutical composition, and its applications. Specifically, this invention provides a compound as shown in formula (II), its pharmaceutically acceptable salt, or its stereoisomer, which can effectively treat or prevent chronic kidney disease, congestive heart failure, hypertension, hypertension complications, or primary aldosteronism; for example, hypertension or primary aldosteronism.

This invention provides a traditional Chinese medicine composition, preparation method, and application for treating uric acid nephropathy, specifically belonging to the field of traditional Chinese medicine preparation technology. The traditional Chinese medicine composition of this invention comprises the following components in parts by weight: Aconitum carmichaelii 3-7 parts, Cinnamomum cassia 1-7 parts, Morinda officinalis 3-10 parts, Sinapis alba 3-9 parts, Fritillaria thunbergii 5-10 parts, Atractylodes lancea 3-9 parts, Coix lacryma-jobi 10-30 parts, Phellodendron chinense 3-12 parts, Pyrrosia lingua 6-15 parts, Dioscorea hypoglauca 9-15 parts, Smilax glabra 15-60 parts, and Prunus persica 5-10 parts. The traditional Chinese medicine composition of this invention can treat uric acid nephropathy, specifically including uric acid nephropathy of kidney yang deficiency type. It has a mild medicinal property, warms the kidney and invigorates the spleen, clears turbidity and detoxifies, and has no toxic side effects.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.

The application discloses a Bifidobacterium longum subsp.longum strain for relieving pathological characteristics of mice with chronic kidney disease induced by adenine, and belongs to the technical fields of microorganisms and medicines.The application provides a biomarker combination related to end-stage renal disease of peritoneal dialysis, wherein the corresponding species abundance in the biomarker combination presents significant difference in matched healthy control population and peritoneal dialysis population, can effectively distinguish the end-stage renal disease population of peritoneal dialysis and the healthy population, and has high sensitivity and specificity.The application also provides a Bifidobacterium longum subsp.longum strain CCFM1375 capable of delaying the progression of renal failure, which can be used for preparing products for improving chronic kidney disease.

The application discloses a group of antibodies specifically recognizing IgA1 with galactose deficiency and related biological materials and application thereof, and belongs to the technical field of antibodies. The main problem to be solved by the application is how to obtain anti-Gd-IgA1 antibodies with high specificity. In order to solve the above technical problem, the application provides antibodies or antigen binding fragments thereof, wherein the antibodies are antibody B0032, antibody B0027, antibody B0025 or antibody B0041. Compared with the existing antibody KM55, the obtained antibodies have higher affinity with antigens, the diagnostic sensitivity and specificity of IgA nephropathy are improved, and the antibodies are expected to be more effectively used for the diagnosis of IgA nephropathy, monitoring of treatment efficacy, judgment of prognosis and the like.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

This invention provides a preventive and / or therapeutic agent for cystic kidney disease. The preventive and / or therapeutic agent for cystic kidney disease comprises a single-stranded oligonucleotide containing a base sequence complementary to at least a portion of the base sequence of miR-21.

The application discloses a diabetic nephropathy pathological model based on human renal tubular epithelial cell organoids and a construction method and application thereof, and belongs to the field of biomedical technology. The construction method comprises the following steps: jointly inducing the renal tubular epithelial cell organoids in a culture medium containing glucose, advanced glycation end products and tumor necrosis factor alpha to prepare the diabetic nephropathy pathological model. The diabetic nephropathy pathological model is constructed by joint induction, the model shows the core pathological phenotypes of diabetic nephropathy, including down-regulation of renal tubular epithelial cell marker expression, up-regulation of fibrosis marker expression, thickening of the basement membrane and abnormal albumin uptake function, the construction method is simple and standardized, the construction period is short, the model has good repeatability and stability, the model has wide application value in high-throughput screening of traditional Chinese medicine monomers or compound medicines with kidney protection, and provides a new platform for mechanism research and treatment strategy development of diabetic nephropathy.

The application relates to a chronic kidney disease prediction method based on clinical information graph representation, belongs to the technical field of computer-aided diagnosis of chronic kidney disease (CKD), and aims to solve the problem of missed diagnosis caused by the fact that the kidney function index of early CKD is not obvious. The incidence of CKD is high, the early symptoms are hidden, and the disease is easy to be missed, thus developing into end-stage renal disease. Therefore, the application provides a chronic kidney disease prediction method based on clinical information graph representation. The method first extracts fundus image and clinical index features; the clinical index is fused into a clinical index joint feature through text embedding and numerical feature fusion, and the joint feature is fused with the fundus image feature through cross-modal attention; the similarity between subjects is calculated based on the fused feature, and a subject relationship graph is constructed by using an adaptive dynamic threshold mechanism; finally, a hybrid graph neural network is used for graph representation learning, pathological similarity between subjects is mined, and accurate prediction of chronic kidney disease is realized. The application can improve the detection rate of early CKD and is applied to non-invasive early screening and risk early warning.

The present application relates to use of a molecular glue compound or a pharmaceutically acceptable salt thereof in preparing a medicament for treating and / or preventing IgA nephropathy.

The application discloses a urine small extracellular vesicle PLA2R1 membrane protein detection method for distinguishing membranous nephropathy, and belongs to the technical field of biomedical detection. The detection method comprises the following steps: preparing an anti-CD63 antibody surface fixed plasmonic metasurface sensing chip to directly capture small extracellular vesicles in urine; preparing an anti-PLA2R1 antibody modified biofunctionalized gold nanoparticle complex to specifically combine with the PLA2R1 membrane protein on the surface of the small extracellular vesicles; detecting the reflection spectrum of the chip after antibody fixation and gold nanoparticle combination through a spectrometer with an integrated optical fiber probe; calculating the resonance wavelength shift amount; measuring the expression level of the PLA2R1 membrane protein; and realizing accurate distinction of healthy people, membranous nephropathy gray area and confirmed patients. The non-invasive detection method is simple in operation and rapid in detection, the sensitivity and the specificity are improved by means of the gold nanoparticle signal amplification effect, and is suitable for large-scale clinical screening and early diagnosis.

The invention provides application of a Parp7 overexpression reagent in preparation of drugs for treating hypertensive nephropathy and protecting acute kidney injury caused by sepsis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the pathological processes of the two diseases can be effectively relieved by increasing the expression level of Parp7 in the renal proximal tubule epithelial cells in a targeted manner. The invention further provides an adeno-associated virus vector comprising a renal proximal tubule epithelial cell specific promoter, a nucleotide sequence encoding Parp7 protein, and a transcription termination signal sequence. Experiments show that the strategy can significantly improve renal function indexes, relieve pathological injury of kidney tissues and inhibit local inflammatory response in an animal model. The invention provides a brand new target spot and gene therapy strategy for the treatment of hypertensive nephropathy and sepsis acute kidney injury.

Methods for treating primary glomerulonephritis, e.g., focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN) or mesangial proliferative glomerulonephritis (MsPGN) are provided.

A method and oral composition for treating a plurality of end-stage diseases, such as end-stage renal disease, chronic kidney disease, liver cirrhosis, chronic liver failure, end-stage liver disease, cancer, congestive heart failure, pulmonary fibrosis, and chronic obstructive pulmonary disease, are disclosed. In one embodiment of the invention, the composition comprises testosterone duodecanoate.

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

The present application relates to the technical field of medical information processing, in particular to an abnormal event automatic classification and recording method in a kidney disease follow-up system, comprising collecting kidney function parameters and symptom codes, identifying abnormal sequences, extracting time anchor points and characteristic identifiers, calculating flip frequency and amplitude, constructing a feature vector to evaluate risk and generating event classification records. In the present application, by constructing an abnormal trigger ordered sequence and extracting anchor points to determine composite features, combining symptom flip frequency to construct a persistence intensity coefficient, quantifying disease complexity from the dimensions of time evolution and etiology coupling, using a multi-dimensional feature vector to fuse physiological amplitude and statistical characteristics, obtaining disease risk probability values through weighted calculation, realizing the transition from qualitative classification to quantitative risk grading, solving the false alarm and missed alarm problems caused by single index determination, providing dynamic diagnosis basis containing risk level for clinical, significantly improving the recognition accuracy and intervention timeliness of the hidden deterioration trend in kidney disease follow-up.

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHS1 or podocin promoter NPHS2.

The present application relates to the precise treatment of kidney disease and the detection technology of intestinal micro-ecological biomarkers, in particular to a biomarker for rapidly screening kidney disease patients treated by leflunomide and application thereof.The present application provides a biomarker for rapidly screening kidney disease patients treated by leflunomide, which can accurately identify whether the patient is an IgAN patient after leflunomide treatment, so as to guide the subsequent medication of the IgAN patient.The results of the specific embodiment of the present application prove that the area under the curve is 0.903, the specificity is 0.83, and the sensitivity is 0.86.

The invention relates to the technical field of diabetic nephropathy onset risk, in particular to an onset risk prediction method and system for type 2 diabetic nephropathy, and the method comprises the following steps: screening characteristic factors through multi-factor Logistic regression, and obtaining contribution degree through principal component analysis; information centralization and decentralization feature weights are constructed based on the contribution degree, and the game theory is introduced for fusion to obtain the optimal feature weight; and finally, inputting the weighted features into the attention guidance double-current time sequence static fusion network which is deeply fused with the optimal weight, and outputting an onset risk. According to the method, contributions of core and secondary indexes are balanced through the game theory, and deep association of static and dynamic data is mined by using a double-flow network, so that the prediction accuracy is remarkably improved.

The present invention relates to the technical field of chemicals, provides a medical use of a compound A or a pharmaceutically acceptable salt thereof, and specifically relates to a use of the compound A or the pharmaceutically acceptable salt thereof in preparation of a drug for preventing or treating nephropathy-related diseases.

The application discloses a research method of a potential protein target point of Guangxi Yaoshan sweet tea against diabetic nephropathy based on proteomics, relates to the technical field of biological medicine, and solves the problem of lacking research on the target point of the action of Yaoshan sweet tea on the prevention and treatment of diabetic nephropathy from the perspective of proteomics. The method comprises the following steps: determining a characteristic active ingredient, namely myricetin, of Yaoshan sweet tea for intervention on diabetic nephropathy, obtaining a PPI network of network pharmacology of the intersection target point of the characteristic active ingredient of Yaoshan sweet tea and diabetic nephropathy; preparing a myricetin solution, preparing a cell disease model and grouping intervention, collecting and pre-treating a cell protein sample, performing mass spectrometry, pre-processing proteomic mass spectrometry data, screening a potential protein target point, identifying and analyzing an expression change trend of the potential protein target point, and analyzing a core protein target point and a key signal path. The application directly locates the key protein target point of Guangxi Yaoshan sweet tea on diabetic nephropathy from a protein expression level, which is more intuitive and more accurate.

The application discloses a RAP polypeptide analogue and medical use thereof, and belongs to the polypeptide medical field, and the amino acid sequence of the RAP polypeptide analogue is Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17, and the N terminal of the RAP polypeptide analogue is acetylated, and the C terminal amino acid is amidated. Compared with the natural RAP polypeptide, the analogue has higher stability, bioavailability and drug efficacy, meanwhile, the dosage is low, the toxic and side effects are not obvious, the production cost is low, and the analogue has good popularization and clinical application prospects. The analogue is suitable for preventing and treating acute and chronic nephritis, chronic nephropathy and renal fibrosis caused by the acute and chronic nephritis, pulmonary inflammation and pulmonary fibrosis caused by the pulmonary inflammation, chronic liver disease and liver fibrosis caused by the chronic liver disease and the like.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

The application provides application of a TAS2R4 agonist in preparation of a drug for treating and preventing diabetic nephropathy, and comprises that a bitter taste receptor 4 subtype (TAS2R4) can be used as a drug target point for treating and preventing diabetic nephropathy, and quinine is used as a TAS2R4 agonist. Specifically, mouse diabetic nephropathy induced by a chemical reagent and mouse podocyte cell line MPC cell damage caused by chronic high glucose are taken as research objects, it is found that mouse TAS2R4 agonist quinine has a prevention and treatment effect on diabetic nephropathy, has a protection effect on podocyte loss caused by high glucose, and has an activation effect on mouse kidney TAS2R4 molecular signal, and a possible molecular mechanism is discussed from the aspects of inhibiting NLRP3 inflammasome activation and NF-kappa B signal activation path, and theoretical basis and technical support are provided for prevention and treatment of diabetic nephropathy, other kidney diseases with inactivation of TAS2R4 molecular signal and other diseases by using TAS2R4 agonists including quinine.

This invention relates to an anti-phospholipase A2 receptor polyclonal antibody, its preparation method, and its application. The preparation method includes immunizing animals with phospholipase A2 receptor protein as an antigen and collecting serum; separating and purifying the serum to obtain the anti-phospholipase A2 receptor polyclonal antibody; the amino acid sequence of the phospholipase A2 receptor protein includes the sequence shown in SEQ ID NO.1. This invention designs specific antigens for the preparation of polyclonal antibodies, enabling efficient preparation of polyclonal antibodies that specifically recognize the phospholipase A2 receptor. It has also been found that polyclonal antibodies prepared using eukaryotically expressed antigens, compared to those prepared using prokaryotically expressed or peptide-derived antigens, can more stably and efficiently construct an anti-PLA2R-associated membranous nephropathy (PLA2R MN) animal model.

This invention relates to a concentrated pill for treating chronic kidney disease, its preparation method, and its application. The raw materials for preparation include the following components: a first extract, a second extract, and pharmaceutically acceptable excipients. The raw materials for preparing the first extract include *Malus kunmingense* (a type of medicinal herb); the raw materials for preparing the second extract include *Epimedium brevicornu*, *Lycium barbarum*, and *Cuscuta chinensis*. This invention improves upon the original dosage form and preparation process of the Kunming-Xian preparation, rationally combining the effective components of each medicinal material to obtain a concentrated pill that effectively treats chronic kidney disease and other diseases, thus better leveraging the clinical efficacy of the Kunming-Xian preparation. Furthermore, through investigation of the extraction and pill-making processes, this invention rationally designs the preparation steps, resulting in a more rational process for the Kunming-Xian concentrated pill, which is more in line with the theoretical basis of traditional Chinese medicine, improves the quality standards of the preparation, has high production efficiency, efficiently utilizes medicinal resources, and has energy-saving, emission-reducing, and environmentally friendly advantages, while also enhancing production safety and meeting the needs of industrial production.